Sjonnie2 schreef op 2 maart 2016 16:11:
[...]
Ik heb even gegoogled en ik vond een oud persbericht uit 2014 van Morphosys met hetzelfde bericht wat Terra2000 hier heeft gemeld, hier een samenvatting:
MOR106 arises from the alliance initiated by Galapagos and MorphoSys in 2008, in which both companies contribute their core technologies and expertise. Galapagos provides the disease-related biology including the target and cellular assays. The targets are discovered using Galapagos' SilenceSelect adenoviral target discovery platform. MorphoSys contributes its Ylanthia antibody technology to generate fully human antibodies directed against the target. Galapagos and MorphoSys will continue to equally share the research and development costs, as well as all future revenues.MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases.
Een klein lijstje van Inflammatory Diseases waarbij de ziekte van Crohn een bekende is voor Galapagos:
A comprehensive list of inflammatory diseases would run to over 100, each of which have high levels of inflammation in the connective tissues, or degeneration of these tissues. These include...
Alzheimer's
ankylosing spondylitis
arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis)
asthma
atherosclerosis
Crohn's disease
colitis
dermatitis
diverticulitis
fibromyalgia
hepatitis
irritable bowel syndrome (IBS)
systemic lupus erythematous (SLE)
nephritis
Parkinson's disease
ulcerative colitis
www.morphosys.com/media-investors/med...